Inclusion Criteria:  Voluntary provision of informed consent. Males or females aged 18-75. Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage IIIB-Ⅳ). At least one lesion can be measured by imaging. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. Life expectancy ≥ 12 weeks. None previous chemotherapy or targeted therapy(Arm:wild-type genotype). Patients should be confirmed acquired EGFR T790M mutation and received adequate EGFR-TKI treatment(Arm:EGFR mutation). Female of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrolment.  Exclusion Criteria:  Histological or cytologically confirmed small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC. Diagnosed with other malignant diseases other than NSCLC within 5 years. Have participated in other interventional clinical research treatments now or within 4 weeks. Have previously received multi-targeted kinase inhibitors therapy. Have active autoimmune diseases requiring systemic treatment within 2 years. Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks. Clinically uncontrollable pleural effusion/abdominal effusion. Vaccinated vaccines or attenuated vaccines within 4 weeks before the group; Pregnant or breastfeeding females. Other serious hazards to the safety of patients.